

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)



(10) International Publication Number
WO 2022/207825 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)

A61K 47/68 (2017.01)

(21) International Application Number:

PCT/EP2022/058629

(22) International Filing Date:

31 March 2022 (31.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21166441.2	31 March 2021 (31.03.2021)	EP
21170941.5	28 April 2021 (28.04.2021)	EP
21172723.5	07 May 2021 (07.05.2021)	EP
21209332.2	19 November 2021 (19.11.2021)	EP

(71) Applicants: **EMERGENCE THERAPEUTICS AG** [DE/DE]; Schifferstr. 210, 47059 Duisburg (DE). **UNIVERSITE D'AIX-MARSEILLE** [FR/FR]; 58 Boulevard Charles Livon, 13007 Marseille (FR). **INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)** [FR/FR]; 101 rue de Tolbiac, 75013 Paris (FR). **INSTITUT JEAN PAOLI & IRENE CALMETTES** [FR/FR]; 232 Boulevard Sainte-Marguerite, 13009 Marseille (FR). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS** [FR/FR]; 3, rue Michel Ange, 75016 Paris (FR).

(72) Inventors: **ELANDS, Jack**; Avenue Clémentine 3, 1190 Forest (BE). **LHOSPICE, Florence**; 2 route de Kervrant, 29770 Primelin (FR). **PRÉVILLE, Xavier**; 502 Chemin de Peire Luche, 06330 Roquefort les Pins (FR). **OLIVE, Daniel**; 56 Avenue Massenet, 13009 Marseille (FR). **LOPEZ, Marc**; Résidence les Cyclades, 2 Allée de la Désirée, 13009 Marseille (FR).

(74) Agent: **WEICKMANN & WEICKMANN PARTMBB**; P.O. Box 860820, 81635 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-NECTIN-4 ANTIBODY EXATECAN CONJUGATES

(57) Abstract: The present invention relates to an antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is a topoisomerase I inhibitor, particularly exatecan.

WO 2022/207825 A1